Alkermes (ALKS): Officer sold ~$112K

~$112K

Approx. value · 3,748 sh @ $30.00

66K

Holds after · shares reported

Traded

Dec 3, 2025

Filed

Dec 5, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 15, 2025InsiderOfficer sold ~$284K of ALKS shares in the open market
2. Oct 22, 2025Company filing · Form 8-K · Material agreement, ResultsSigned an important agreement, and reported its results (and 2 more items)
3. Oct 28, 2025Company filing · Form 8-K · ResultsReported its results
4. Nov 3, 2025InsiderOfficer sold ~$273K of ALKS shares in the open market
5. Nov 18, 2025Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 1 more item)
6. Dec 1, 2025InsiderOfficer sold ~$117K of ALKS shares in the open market
7. Dec 3, 2025 · this disclosureInsiderOfficer sold ~$112K of ALKS shares in the open market

What came next

1. Jan 2, 2026InsiderOfficer sold ~$112K of ALKS shares in the open market
2. Jan 8, 2026InsiderOfficer sold ~$150K of ALKS shares in the open market
3. Jan 12, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
4. Feb 2, 2026Insider · 2 peopleInsiders: 4 sales (~$2.4M)
5. Feb 12, 2026Company filing · Form 8-K · Material agreement, Agreement endedCompleted buying or selling a business or assets, and signed an important agreement (and 3 more items)“On February 12, 2026, the Company and Avadel Pharmaceuticals plc (“Avadel”), completed the transactions contemplated by the previously announced Transaction Agreement (the “Original Transaction Agreement”) dated October 22, 2025, as amended by Amendment No.1 to the Transaction Agreement (the “Amendment”) dated November 18, 2025, by and between the Company and Avadel (as amended, the “Transaction Agreement”).”
6. Feb 24, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On February 24, 2026, Richard F. Pops, Chairman and Chief Executive Officer of Alkermes plc (the “Company”), notified the Company’s board of directors (the “Board”) of his decision to retire from his position of Chief Executive Officer, effective July 31, 2026, following a distinguished 35 years of service in this role.”
7. Feb 25, 2026Company filing · Form 8-K · ResultsReported its results
8. Mar 2, 2026Insider · 4 peopleInsiders: 4 sales (~$709K)
9. Mar 3, 2026InsiderOfficer sold ~$61K of ALKS shares in the open market
10. Apr 1, 2026InsiderOfficer sold ~$320K of ALKS shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Alkermes

For Alkermes, OQRO holds 8 insider filings (SEC Form 4 or Form 144) and 2 Congress trade reports dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ALKS page.

Other recent filings by Craig C. Hopkinson, EVP R&D, Chief Medical Officer

• SEC Form 4 at Alkermes (ALKS)Sep 1, 2026
• SEC Form 4 at Alkermes (ALKS)Aug 3, 2026
• SEC Form 4 at Alkermes (ALKS)Jul 1, 2026
• SEC Form 4 at Alkermes (ALKS)Jul 1, 2026
• SEC Form 4 at Alkermes (ALKS)Jun 1, 2026

The full history of Craig C. Hopkinson, EVP R&D, Chief Medical Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Alkermes

• SEC Form 4Nov 4, 2026
• SEC Form 144Nov 3, 2026
• House Clerk periodic transaction reportOct 12, 2026
• SEC Form 4Oct 2, 2026
• SEC Form 144Oct 2, 2026
• House Clerk periodic transaction reportSep 4, 2026

Everything OQRO holds on this company is on its ALKS page.